Investment Firm, Stanford Form Private Health Research Company

<p><a href&equals;"https&colon;&sol;&sol;www&period;stanford&period;edu&sol;">Stanford University<&sol;a> is teaming up with <a href&equals;"https&colon;&sol;&sol;deerfield&period;com&sol;">Deerfield Management<&sol;a>&comma; a New York-based health care investment firm&comma; to create Porter Alliance for Innovative Medicines that will accelerate translational research into clinical therapeutics&period;<&sol;p>&NewLine;<p>Deerfield has committed up to &dollar;130 million and additional scientific and operational support to this new collaboration to advance research coming out of Stanford faculty laboratories with a focus on drug prototypes emerging from Stanford’s <a href&equals;"https&colon;&sol;&sol;ima&period;stanford&period;edu&sol;">Innovative Medicines Accelerator<&sol;a>&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The Porter Alliance for Innovative Medicines aims to close a historic gap between scientific research and clinical care&comma;” said <a href&equals;"https&colon;&sol;&sol;med&period;stanford&period;edu&sol;profiles&sol;lloyd-minor">Lloyd Minor<&sol;a>&comma; MD&comma; dean of the <a href&equals;"https&colon;&sol;&sol;med&period;stanford&period;edu&sol;">Stanford University School of Medicine<&sol;a>&period; &OpenCurlyDoubleQuote;This collaboration with Deerfield Management will ensure that Stanford’s breakthroughs in biomedical research translate rapidly to treatments and cures for patients&period;”<&sol;p>&NewLine;<p>The newly launched Porter Alliance for Innovative Medicines is a private company that will be wholly owned by affiliates of Deerfield Management&period; Its objective is to fund projects that have uncovered novel therapeutics that have the potential to cure life-altering diseases&period; This collaboration will rely on the robust and diverse drug pipeline already established by Stanford’s Innovative Medicines Accelerator&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We are proud to collaborate with Stanford University to help build the bridge that connects basic research to patient cures&comma;” said James Flynn&comma; managing partner at Deerfield Management&period; &OpenCurlyDoubleQuote;It requires tremendous infrastructure and support to change the probability of success and speed to market for discovery&period; Through Porter Alliance&comma; Stanford investigators will receive the necessary resources&comma; expertise and management to advance their outstanding science&period;”<&sol;p>&NewLine;<p>The collaboration will be governed by a joint steering committee comprising equal representation from Deerfield and Stanford University&period; Stanford researchers will be encouraged to submit proposals for consideration for execution through the collaboration&period;  Accepted proposals will receive a development plan aimed at achieving investigational new drug readiness&period; Selected proposals will also have the eligibility for additional capital investments to create spin-off companies&period;<&sol;p>&NewLine;<p>The Porter Alliance connects Stanford to the broader biopharmaceutical industry and helps researchers understand the problems they need to solve to make transformative medicines&period; A key partner in the collaboration is the Innovative Medicines Accelerator&comma; established as part of Stanford’s vision to be a more purposeful university by turning breakthrough discoveries into solutions for the world&&num;8217&semi;s most pressing problems&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The Innovative Medicines Accelerator is helping Stanford faculty transform their discoveries into prototype medicines&comma; and we must do whatever we can to ensure those medicines get to the patients who need them&comma;” said <a href&equals;"https&colon;&sol;&sol;profiles&period;stanford&period;edu&sol;chaitan-khosla">Chaitan Khosla<&sol;a>&comma; PhD&comma; director of the Innovative Medicines Accelerator and professor of chemistry and of chemical engineering at Stanford University&period; &OpenCurlyDoubleQuote;I am excited and grateful that the Porter Alliance for Innovative Medicines will serve as a bridge between our promising prototypes and approved therapeutics&period;”<&sol;p>&NewLine;

Editor

Nirvana Lands $100 Million Series D

SAN FRANCISCO -- Nirvana Insurance, an AI-native commercial insurer, has secured a preemptive $100 million…

5 days

Kargo Scores $42 Million Series B

SAN FRANCISCO -- Kargo, a provider of industrial artificial intelligence (AI) technology for supply chain…

5 days

Instacart to Pay $60 Million to Settle FTC Lawsuit

The Federal Trade Commission announced that grocery delivery provider Instacart will pay $60 million in…

5 days

ServiceNow to Buy Armis for $7.75 Billion

SANTA CLARA -- ServiceNow has agreed to buy Armis for $7.75 billion in cash. Armis…

5 days

Six Companies Added to Nasdaq 100

The Nasdaq stock market has reformulated the list of 100 companies in the Nasdaq-100 Index…

1 week

NVIDIA Acquires SchedMD

NVIDIA says it has acquired SchedMD — the leading developer of Slurm, an open-source workload…

1 week